Business Context and Reporting Period
MEDICINOVA INC filed this Form 8-K on August 16, 2011, to disclose a Japanese financial report ("Kessan Tanshin") filed with the Osaka Securities Exchange. The report covers the quarter ended June 30, 2011, and provides updated full-year guidance for the fiscal year ending December 31, 2011.
Key Financial Metrics and Guidance
The filing provides full-year 2011 estimates rather than specific quarterly results for the period ended June 30, 2011. Key metrics for the full year 2011 include:
- Revenues: $0 (No revenue expected).
- Operating Loss: $(15,721,000).
- Net Loss: $(18,678,000).
- Loss Per Share: $1.28 (Basic and diluted, based on 14,643,992 weighted average shares).
- Cash Burn: Anticipated to be less than $31.8 million for the fiscal year.
- Debt Repayment: Includes a $15.2 million debt repayment made in April 2011.
Supplementary financial statements denominated in Japanese yen were translated at a rate of 77.85 yen per U.S. dollar.
Material Changes and Outlook
Management confirmed that the estimated results for the full year ending December 31, 2011, remain unchanged from the guidance previously provided on May 17, 2011. The company continues to operate with no expected revenue and significant net losses driven by development costs.
Risks, Contingencies, and Management Commentary
Management cautioned that these estimates are based on assumptions subject to significant risks and uncertainties. Key risk factors include:
- Clinical Trials: Uncertainty regarding results, delays, enrollment issues, and regulatory approval for product candidates.
- Third-Party Reliance: Risks associated with third parties conducting clinical trials and manufacturing.
- Strategic Integration: Challenges in integrating the Avigen, Inc. acquisition and combining ibudilast development programs.
- Liquidity: The ability to raise sufficient capital to complete product development plans.
- Market Conditions: Potential impairments to the investment portfolio due to credit and capital market uncertainties.
Independent auditors have not compiled or reviewed these forecasted results and assume no responsibility for their accuracy.
Investor Verification Checklist
- Verify the company's current cash position and runway against the stated cash burn of less than $31.8 million.
- Confirm the status of the Avigen, Inc. integration and the combined ibudilast development program.
- Review the Form 10-K for the year ended December 31, 2010, for detailed risk factors referenced in this filing.
- Monitor upcoming clinical trial milestones and regulatory filings for product candidates.
- Assess the company's ability to secure additional capital given the projected net loss of approximately $18.7 million.